Abstract
About half of luminal and triple negative breast cancers (TNBC) show low HER2 expressions. These HER2-low breast cancers (BC), with a HER2 IHC score of 1+ or 2+ with negative ISH, are emerging as a new druggable entity, related to the development of novel anti-HER2 antibody-drug conjugates. Little data is available on the evolution of low HER2 expressions between early and metastatic BC (mBC).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
